Close Menu

financial results

Due to a ransom cyberattack on its information technology systems, the firm reported full revenue but only preliminary earnings estimates.

The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.

The company said revenues declined primarily as a result of adjustments in accounts receivable, payor mix, and the timing of test kit collections.

The company posted higher total sales for the first half of its fiscal year 2020 on sales growth in both in Japan and internationally.

The liquid biopsy firm reported revenues of $60.8 million for the quarter, easily surpassing the consensus Wall Street estimate of $45.4 million.

The company's software-related revenues grew year over year, but its sequencing and molecular analysis revenues declined.

Total revenue during the third quarter was impacted by lower product sales in Africa, but the firm said it saw growth in the US, Latin America, and Asia Pacific.

The firm missed Wall Street expectations due in part to an elongated sales cycle and the timing of commercial go-lives.

As a result of its collaboration with Quest Diagnostics, Oxford Immunotec is experiencing a surge in orders from physician offices for its interferon gamma release assay TB kits.

The firm's diagnostics revenues decreased 9 percent to $33.4 million, and life sciences revenues increased 7 percent to $17.4 million.

Pages